Capital Fund Management S.A. increased its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 338.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,317 shares of the company’s stock after buying an additional 49,663 shares during the period. Capital Fund Management S.A. owned 0.15% of ABIOMED worth $8,270,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ABMD. Cypress Capital Management LLC WY acquired a new stake in ABIOMED during the second quarter valued at approximately $106,000. Creative Planning increased its position in shares of ABIOMED by 53.3% in the third quarter. Creative Planning now owns 984 shares of the company’s stock worth $127,000 after buying an additional 342 shares during the period. Private Bank & Trust Co. purchased a new position in shares of ABIOMED during the third quarter worth about $203,000. Advisor Group Inc. purchased a new position in shares of ABIOMED during the second quarter worth about $204,000. Finally, Gilder Gagnon Howe & Co. LLC increased its position in shares of ABIOMED by 3.5% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,969 shares of the company’s stock worth $215,000 after buying an additional 67 shares during the period. Institutional investors own 91.46% of the company’s stock.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Shares of ABIOMED, Inc. (NASDAQ:ABMD) traded up 0.12% on Friday, reaching $112.50. 33,423 shares of the company’s stock were exchanged. ABIOMED, Inc. has a one year low of $67.81 and a one year high of $132.95. The company has a 50 day moving average price of $114.11 and a 200 day moving average price of $116.94. The firm has a market cap of $4.85 billion, a PE ratio of 115.98 and a beta of 0.49.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, October 27th. The company reported $0.20 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.24 by $0.04. ABIOMED had a net margin of 11.24% and a return on equity of 11.63%. The company had revenue of $103 million for the quarter, compared to analysts’ expectations of $103.16 million. During the same period in the previous year, the firm earned $0.17 earnings per share. The firm’s quarterly revenue was up 35.0% on a year-over-year basis. Analysts expect that ABIOMED, Inc. will post $1.13 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is the propert of of Daily Political. If you are accessing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at http://www.dailypolitical.com/2017/01/13/abiomed-inc-abmd-shares-bought-by-capital-fund-management-s-a.html.

ABMD has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of ABIOMED from a “hold” rating to a “sell” rating in a research report on Thursday, January 5th. Guggenheim began coverage on shares of ABIOMED in a research note on Tuesday, December 6th. They set a “buy” rating and a $150.00 price target for the company. Leerink Swann restated an “outperform” rating and set a $125.00 price target on shares of ABIOMED in a research note on Wednesday, September 28th. TheStreet lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Thursday, October 27th. Finally, BTIG Research reaffirmed a “buy” rating and set a $170.00 price objective on shares of ABIOMED in a report on Sunday, January 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $138.71.

In related news, Director Dorothy E. Puhy sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $120.00, for a total value of $960,000.00. Following the transaction, the director now directly owns 32,749 shares of the company’s stock, valued at approximately $3,929,880. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.00% of the stock is owned by corporate insiders.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

5 Day Chart for NASDAQ:ABMD

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.